Assessing the human health impacts of exposure to disinfection by-products - A critical review of concepts and methods by Grellier, James et al.
Environment International 78 (2015) 61–81
Contents lists available at ScienceDirect
Environment International
j ourna l homepage: www.e lsev ie r .com/ locate /env intReviewAssessing the human health impacts of exposure to disinfection
by-products — A critical review of concepts and methods☆James Grellier a,b,c,d,⁎, Lesley Rushton d, David J. Briggs d, Mark J. Nieuwenhuijsen a,b,c,d
a Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
b Universitat Pompeu Fabra (UPF), Barcelona, Spain
c CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
d Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College, London, United Kingdom☆ Funding: This research was supported by the Integra
Commission Sixth Framework Programme (2002–2006) g
⁎ Corresponding author at: CREAL — Centre for Resea
Barcelona, Spain.
E-mail address: jgrellier@creal.cat (J. Grellier).
http://dx.doi.org/10.1016/j.envint.2015.02.003
0160-4120/© 2015 Elsevier Ltd. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 9 July 2014
Received in revised form 28 January 2015
Accepted 1 February 2015
Available online 11 March 2015
Keywords:
Risk assessment
Disinfection by-products
Chloroform
Health impact assessment
Health risks
CancerUnderstanding the public health implications of chemical contamination of drinking water is important for soci-
eties and their decision-makers. The possible population health impacts associatedwith exposure to disinfection
by-products (DBPs) are of particular interest due to their potential carcinogenicity and their widespread occur-
rence as a result of treatments employed to control waterborne infectious disease.
We searched the literature for studies that have attemptedquantitatively to assess population health impacts and
health risks associated with exposure to DBPs in drinking water. We summarised and evaluated these assess-
ments in terms of their objectives, methods, treatment of uncertainties, and interpretation and communication
of results.
In total we identified 40 studies matching our search criteria. The vast majority of studies presented estimates of
generic cancer andnon-cancer risks based on toxicological data andmethods thatwere designedwith regulatory,
health-protective purposes in mind, and therefore presented imprecise and biased estimates of health impacts.
Many studies insufficiently addressed the numerous challenges to DBP risk assessment, failing to evaluate the ev-
idence for a causal relationship, not appropriately addressing the complex nature of DBP occurrence as amixture
of chemicals, not adequately characterising exposure in space and time, not defining specific health outcomes,
not accounting for characteristics of target populations, and not balancing potential risks of DBPs against the
health benefits related with drinking water disinfection. Uncertainties were often poorly explained or insuffi-
ciently accounted for, and important limitations of data andmethods frequently not discussed. Grave conceptual
andmethodological limitations in studydesign, aswell as erroneoususe of available dose–response data, serious-
ly impede the extent to which many of these assessments contribute to understanding the public health impli-
cations of exposure to DBPs. In some cases, assessment results may cause unwarranted alarm among the
public and potentially lead to poor decisions being made in sourcing, treatment, and provision of drinking
water. We recommend that the assessment of public health impacts of DBPs should be viewed as a means of
answering real world policy questions relating to drinking water quality, including microbial contaminants;
that they should be conducted using themost appropriate and up-to-date data andmethods, and that associated
uncertainties and limitations should be accounted for using quantitative methods where appropriate.
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801. Introduction
Maintaining high microbial quality of drinking water is a cornerstone
of public health, and chemical disinfection with chlorine and its com-
pounds commonly forms a key component in drinking water treatment.
Disinfection by-products (DBPs) may result from reactions between dis-
infectants and impurities in source water and their occurrence has been
a public health concern for the last four decades.
DBPs were first identified in the form of trihalomethanes (THMs)
(Bellar et al., 1974; Rook, 1974). By concentration, THMs represent the
most prevalent group of DBPs in typical chlorinated drinking water,
but many hundreds of other DBPs also occur (Nieuwenhuijsen et al.,
2000a; WHO, 2006), several of which are potentially carcinogenic
(Richardson et al., 2007). The ~600 DBPs that have been identified
(Richardson, 1998; Richardson et al., 2007) represent only a small frac-
tion of the total organic halides present in chlorinated supplies (USEPA,
1998), and relatively few of those chemicals have been adequately
characterised in terms of occurrence. Fewer still have been assessed in
terms of their potential effects on human health (Richardson et al.,
2007).
The occurrence of DBPs has become an issue of interest to policy
makers, drinking water providers and engineers, epidemiologists,
biologists and risk assessors, particularly since they are a side effect of
disinfection with chlorine, which commonly plays an important role
in minimising public health risks of waterborne infectious diseases.
The concentrations of DBPs vary temporally and geographically accord-
ing to the physicochemical properties of source water, the nature of
treatment and distribution systems, and climate (Amy et al., 2000;
Nieuwenhuijsen et al., 2000b), whichmakes characterisation of general
population exposures for the purposes of epidemiological studies and
population health impact assessments complex.
Epidemiological studies based on routinemonitoring data (e.g. THM
concentrations measured at individual residences as a proxy for an
unknown putative agent in the DBP mixture) have been carried out
for several cancers and several non-cancer health endpoints, in particu-
lar birth outcomes (Nieuwenhuijsen et al., 2013). Various systematic re-
views, meta-analyses and pooled analyses of cancer studies have also
been produced (Amy et al., 2000; Cantor, 1997; Morris et al., 1992;
Nieuwenhuijsen et al., 2009a; Villanueva et al., 2003), these show no
consistent evidence of associations between DBP exposure and the ma-
jority of cancers (Amy et al., 2000). Consistent, positive associations
have been found only for bladder cancer: meta- and pooled analyses
have demonstrated exposure–response relationships between average
residential THM concentrations and bladder cancer in men (Costet
et al., 2011; Villanueva et al., 2003, 2004). In terms of non-cancer out-
comes, small positive associations have been reported for still births
(Nieuwenhuijsen et al., 2010), small for gestational age (Grellier et al.,
2010) and congenital anomalies (Nieuwenhuijsen et al., 2009b). For
all of these health outcomes, epidemiological evidence is currently not
sufficient to infer whether such associations are causal.
Regulatory limits for DBPs have been developed chiefly from data
derived from animal toxicological studies. EU guidelines specify aparametric value of 100 μg/L for the four most prevalent THMs (THM4)
(European Commission, 1998); the maximum contaminant level in the
US is currently 80 μg/L for THM4 (USEPA, 1998). Five haloacetic acids
are also regulated in the US, as well as bromate and chlorite (USEPA,
2013). In each case, limits have been set according to available scientific
knowledge and account was taken of the precautionary principle, such
that life-long consumption of water meeting the guideline values should
afford the public protection from adverse health effects. However,
cytotoxicological and genotoxicological studies of currently unregulated
DBPs indicate that many may be considerably more toxic to humans
than THMs or HAAs (Plewa and Wagner, 2009; Plewa et al., 2004, 2008;
Richardson et al., 2007). Although THMs make up a high proportion of
DBPs in chlorinated drinking water by concentration, it is plausible that,
as more data become available on the occurrence and carcinogenicity of
some of these unregulated DBPs, the relevance of THMs as a carcinogenic
risk factor will diminish considerably (Bull, 2012).
Risk assessment carried out with the aim of determining regulatory
limits involves extensive review of both epidemiological and toxicolog-
ical data. Animal studies tend to be relied upon for providing quantita-
tive dose–response data. Measures of cancer potency—referred to as
either potency factors (PF) or slope factors (SF)—are derived by model-
ling animal carcinogenicity data for each applicable exposure pathway
(ingestion, inhalation and dermal absorption) for the most sensitive
cancer endpoint. For a suspected genotoxic carcinogen, it is assumed
that exposure at any level increases the probability of cancer. The
linearisedmultistage (LMS)model (Crump, 1984) has been used exten-
sively as the default means of extrapolating from the high doses used in
animal studies to the lower doses typically experienced by humans.
Usually, cancer potency factors are defined using the 95% upper bound
of the LMS regression line so as to allow for uncertainties resulting
from extrapolation from animals to humans, and from differences in
the exposure regimes. In order to calculate regulatory limits, lifetime ex-
posure of a typical human to a potential carcinogen in drinking water is
then estimated via each applicable exposure pathway (drinking, wash-
ing, showering etc.). An upper bound estimate of lifetime excess cancer
risk (LECR)—the lifetime probability of a typical individual developing a
cancer—is then estimated by summing the products of exposure
through each route by its appropriate potency factor, according to the
procedure described by Chrostowski (1994), Gratt (1996) and USEPA
(2002a):
LECR ¼
X
LAEi  PFi
where LAE is the lifetime average exposure (mg), PF is the potency
factor ((mg/kg-day)−1), and i is the exposure route (ingestion, inhala-
tion and absorption). Since the LECR is based on potency factors derived
from the upper bound of the LMS model, it can be considered a conser-
vative overestimate that should be protective of public health. Regulato-
ry guidelines use this information to set a concentration of a chemical in
drinking water at which the lifetime risk of cancer is considered
acceptable (commonly between 1 × 10−4 and 1 × 10−6, depending
on circumstances).
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calculated from the same estimate of LAE divided by a reference dose
(RfD), which is a measure of the potential of a systemic toxic effect in
a lifetime of exposure, again commonly derived from animal data. In
contrast to genotoxic carcinogenic effects, systemic effects are considered
to occur only above an identifiable threshold of exposure at which the
body's capacity to detoxify an agent through homeostasis and adaptive
mechanisms is exceeded. In order to derive an RfD from animal data, it
is necessary, firstly, to identify the no observed adverse effect level
(NOAEL), the dose at which no biologically or statistically significant ef-
fects are observed in study animals. To estimate a level at which human
health is protected, theNOAEL is then divided by a number of uncertainty
factors (each typically equal to 10), to account for: (a) variation in sensi-
tivity between among members of the human population;
(b) uncertainty involved in extrapolating from animal data to humans;
and (c) for extrapolation fromsubchronic assays to chronic exposure con-
ditions. The RfD can thus be considered the threshold of exposure at
which there is no appreciable risk of deleterious systemic effects over a
lifetime. Hence, an HQ of less than unity indicates that an individual
should not experience adverse non-carcinogenic health effects.
Outside of the regulatory sphere, there are other decision-making
contexts in which it is useful to estimate the health impacts associated
with exposure to environmental exposures as accurately as possible,
without employing conservative, public health-protective assumptions.
For the purposes of this review, we broadly refer to such efforts as
population health impact assessments, although many other terms
have been used to describe such studies (Briggs, 2008). Over the
last few decades, several studies have been carried out with popula-
tion health impact assessment as an aim, but which utilise methods
and data developed for regulatory risk assessment. Conspicuously fewer
population health impact assessments have been done using epidemio-
logical data, or for the purposes of looking at benefits of disinfection ver-
sus possible health risks associated with resultant DBPs.1.1. Aims and objectives
We sought to identify and describe published studies that aim to
estimate population health impacts related to exposure to DBPs,
with a view to assessing how well this objective has been met in
the literature to date. Our specific objectives were to identify the
methods used to quantify health risks and impacts, to review the
means by which various types of uncertainty were accounted for,
and to discuss the ways in which results of such assessments have been
interpreted, contextualised, and presented (risk communication). We
aimed to provide recommendations for the improvement of population
health impact assessment related to exposure to DBPs, and to environ-
mental stressors more generally.2. Materials and methods
A literature search was carried out to identify studies claiming to as-
sess population health impacts of exposure to DBPs in drinking water
(search method presented in Supplementary material 1). Studies were
considered eligible if they presented quantitative predictions of health
impact or health risk associated with exposure to DBPs for an identified
human population.We reviewed all identified studies in detail and their
main featureswere summarised, focusing in particular on hazard/agent,
health outcomes, exposure assessment, target populations, risk charac-
terisation, temporal character, scenarios or policy questions analysed,
analysis of uncertainties, and interpretation and presentation of the as-
sessment results. Detailed review of the studies allowed us to evaluate
the strengths and shortcomings of methods typically used, and to make
recommendations onhowassessment of populationhealth impacts of ex-
posure to DBPs might be improved.3. Results and discussion
In total, we identified 40 population health impact assessment
studies that met our eligibility criteria for inclusion in this review
(Table 1).
3.1. Populations
The populations defined in the majority of studies were those of
individual countries, regions, cities or those served by individual
waterworks or distribution systems. Eight studies were done in
Canada, 8 in the USA, 5 in Turkey, 3 in China (one jointly reported
with a Canadian study), 2 in Korea, 2 in Pakistan, 2 in Taiwan, and one
each in Brazil, Germany, Hong Kong, India, Italy, Japan, Lebanon,
Mexico, the Netherlands and New Zealand. Hypothetical populations
were defined in 2 studies (Black et al., 1996; Havelaar et al., 2000),
and one laboratory-based study focused on 6 subjects exposed to DBPs
under experimental conditions (Jo et al., 1990). In one study, sensitive
population subgroups were identified, comprising women of reproduc-
tive age and developing foetuses (USEPA, 2005). Surveyed demographic
characteristics pertaining to these populations (in terms of sex- or age-
structure) were taken into account in few assessments, and commonly
existing general point estimates or distributions of body weight, water
consumption rates, inhalation rates etc. were used when characterising
exposures. In some cases not taking into account the demographic
structure or behavioural characteristics of populations may result
in a misclassification of the risk status of certain population strata.
For example, bladder cancer has been found to be associated with
DBPs only in males, and incident cases occur extremely infrequently
in those below the age of 40 years. Estimation of numbers of cases attrib-
utable to exposure to DBPs should be made with adequate consideration
of both age and sex stratification of the target population.
3.2. Hazard/agent
Twenty-four studies investigated solely THM4, 8 studies focused
only on trichloromethane (TCM), and 5 studies looked at THM4 and
some HAAs. One study focused on TCM, bromodichloromethane
(BDCM) and dibromochloromethane (DBCM) only. One study looked
at ingestion of bromate, which is produced due to disinfection with
ozone, and one used residence in a zone where drinking water was
chlorinated as an indicator of DBP exposure. Only one study explicitly
considered contamination of drinking water by pathogens (specifically
Cryptosporidium parvum), in spite of the very clear policy need for as-
sessments in which cancer risks associated with DBPs are balanced
with the benefits of disinfection (Havelaar et al., 2000).
3.3. Health outcomes
Almost all studies focused on the risk of cancer, with the vast major-
ity of studies estimating LECR rather than risks of specific cancers. This
method requires the use of PFs that are derived from themost sensitive
tumour endpoint in a set of animal studies. Although theoretically this
is protective against other cancers, it cannot be assumed that this
same endpoint would be that occurring in humans. As such, the degree
to which the LECR calculated provides an upper bound estimate of risk
of any cancer is unknown. Five studies looked at specific cancers:
bladder cancer (Attias et al., 1995; Malcolm et al., 1999; USEPA,
2005), colorectal cancer (Malcolm et al., 1999; USEPA, 2005), and
renal cell cancer (Havelaar et al., 2000). Generic non-carcinogenic
risks were estimated in 14 studies, quantified using hazard quotients
(or hazard indices). Specific non-cancer outcomes included microbial in-
fections (Havelaar et al., 2000), foetal loss (USEPA, 2005), and birth de-
fects (Malcolm et al., 1999).
Metrics such as LECR and HI are not particularly informative in
population health impact assessment. Upper bound estimates of LECR
Table 1
Summary of health risk and impact assessments of drinking water disinfection by-products.
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cer on society in terms of type, severity, survival times, population sub-
groups affected, associated effects on quality of life or costs to healthcare
providers. Also, they do not provide useful information on potential
health benefits that might be associated with policies or interventions
that might alter exposures, either deliberately or as an unintended con-
sequence. Use of data and methods that allow estimation of the burden
of specific health outcomeswould result inmore useful information to a
range of decision-makers, as was done in those studies that derived ex-
posure–response data from epidemiological studies. In the Havelaar
et al. (2000) study, themaximum likelihood estimate of risk of a specific
cancer outcome (renal cell cancer) derived from animal data was ex-
plicitly assumed to correspond to the same outcome in humans, and
the implications to public health estimated in terms of the severity
and duration of that outcome. In one assessment, estimates of LECR
were monetised using cost models for bladder and colorectal cancers
(Chowdhury et al., 2011), although it later transpired that the methods
used in this paper were wrong (Bull et al., 2012). Revised estimates
were subsequently published, indicating that the original LECRwas con-
siderably overestimated (Chowdhury, 2012). When correctly applied,
such an approach might seem to be an improvement over estimates of
LECR-based lifetime cancer cases, although the generic nature of LECR
limits its validity and we would recommend the more appropriate use
of epidemiological data in deriving estimates of attributable cases of a
specific cancer outcome. Although epidemiological data on specific
health outcomes were used in the USEPA (2005) assessment, estimates
of lifetime cancer risk based on slope factors were presented for the
purposes of comparison. Notably, these were presented alongsideappropriate caveats regarding the limitations associated with use and
interpretation of such data.
3.4. Exposure assessment
Apart from the laboratory-based, experimental study reviewed
(Jo et al., 1990) and study of biomarkers of exposure (LaKind et al.,
2010), all studies employed one of three types of exposure assessment:
(1) ecological assessments, where populations were assigned exposure
levels based onmeasured ormodelled concentrations of DBPs in drinking
water; (2) individual level assessment, where a survey of measurements
was undertaken for each subject; or (3) binary ecological assessment,
where the populationwas divided according towater supply chlorination
status in their area of residence. The first of thesemethodswas usedmost
frequently, with DBP concentrations in drinking water supplies being
derived from sampling surveys or monitoring data. In some cases, how-
ever, DBP concentrations were entirely based on models, using typical
source water quality and treatment procedures as input variables (Black
et al., 1996; Havelaar et al., 2000), or on complex semi-empirical models
developed using monitoring data and treatment plant characteristics
(USEPA, 2005).
Given concentrations of DBPs in drinkingwater, exposurewas calcu-
lated either solely for the ingestion pathway, or via multiple pathways.
Several process-basedmodelswere used to calculate the concentrations
of DBPs taken into the body. This multipathway approach is based on
various USEPA regulatory risk assessment guidelines (USEPA, 1986,
1999, 2002b) and was introduced into the field of assessing population
health impact of DBPs by Lee et al. (2004); many of the subsequent
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kind of assessment.
In those studieswhere ingestionwas considered as the sole pathway
of exposure, those pathways inwhich volatility of DBPs plays an impor-
tant role were ignored. While this is not necessarily a problem for non-
volatile components of the DBP mixture, it is a serious problem for
THMs, since net exposure may in fact be dominated by inhalation dur-
ing bathing or showering (Nieuwenhuijsen et al., 2000b; Richardson,
2005). In some studies, TCM was used as an indicator for THM4. We
would strongly recommend against such an approach: differences in
volatilities of individual THMs, in correlations between TCM and the
other THMs throughout the distribution network, and in the likely
modes of toxicity of individual THMs are all likely to bias risk prediction
estimates.
Duration of sampling surveys or periods of monitoring data varied
between 2 weeks (Navarro et al., 2007) and 6 years (Williams et al.,
2002). In some cases, no information was given regarding the timing
or duration of sampling surveys (e.g. Amjad et al. (2013)), which
makes the results impossible to interpret. Variations in past exposure
were typically ignored. Extrapolation of current levels through time
may ormay not be valid depending on the temporal stability of contam-
inant levels in the drinking water sources, methods and technologies
employed at treatment plants, and characteristics of the distribution
network.When risks based on short termor point estimates of exposure
are applied to a population in calculating LECR, for example, those
exposure estimates are considered valid averages for 70 years. It has
been shown, however, that there is a considerable degree of variability
in THM concentrations both within and between 24-hour samples (e.g.
Smith et al., 1980; Rodriguez and Serodes, 2001), on a seasonal basis
(e.g. Parvez et al., 2011), and among year-on-year averages (e.g.
Toledano et al., 2005). Usage habits of water might also be expected to
change considerably in time: e.g. tap water consumption to bottled
water, bathing to showering, hand washing of clothes and dishes to
automatic washing. Calculating health impacts without considering
possible changes in exposure over time is particularly problematic for
carcinogens, since the bladder cancers associated with exposure to
DBPs in epidemiological studies are characterised by long latency
times. The USEPA (2005) assessment explicitly incorporated such tem-
poral components in modelling regulatory compliance related to
implementing a new rule, and in modelling cessation lag (period be-
tween reduction in exposure to a carcinogen and that point when the
full risk reduction benefit is realised by affected individuals).
In some studies, concentrations of DBPs at the DWTP were used as
exposure estimates for the target population (e.g. Black et al., 1996).
DBP concentrations are known to vary considerablywithinwater distri-
bution networks (Amy et al., 2000); levels of THMs have been found to
increase with residence time, while other DBPs have been found to de-
crease (haloacetonitriles, haloketones, chloropicrin, and haloacetic
acids) (Chen and Weisel, 1998). Ideally, concentrations of DBPs at the
individual consumer taps would be used to characterise target popula-
tion exposure. Where concentrations at the tap are not available for
the entire target population (or are available only at a poor spatial res-
olution), relationships between concentrations of DBPs at the DWTP
and at different points within the distribution network should be ex-
plored and quantified.
Geographical information systems (GIS) were used in two studies to
produce risk maps based on spatial exposure data. Venkataraman and
Uddameri (2012) used TTHM monitoring data and groundwater pa-
rameters from a very limited number of locations to model TTHM con-
centrations at those locations, and krigingwasused to interpolate TTHM
concentrations across a large area (some 30,000 miles2). Karim et al.
(2013) used kriging of data from a TTHM sampling survey (at 30 loca-
tions) to estimate TTHM concentrations for several million inhabitants.
As DBP concentrations do not vary smoothly in space, but tend to vary
heterogeneously and unpredictably according to the configuration of
the network, we consider that neither approach would produceanything other than extremely unreliable exposure estimates for the
target populations concerned.
In general, the effort invested in very detailed exposure models in
support of an assessment that then uses regulatory tools such as PFs
to estimate riskmay not be rewarded in terms of proportional improve-
ments in the risk assessment results. In such cases, we would propose
that it would be more efficient—and useful from the point of view
of informing public health policy—to invest more effort in better
characterising the exposure–response functions used. Such risk assess-
ment research should generally be geared towards optimising the use
of limited risk management resources (Jardine et al., 2003). In the
study by Lee et al. (2004), and several assessments using the same
methodology (Tokmak et al., 2004; Viana et al., 2009; Wang et al.,
2007a,b), the authors compare cancer risks according to individual tri-
halomethane species through single exposure pathways. For example,
a very detailed process-basedmodel of exposure during showering sup-
ports a risk assessment that presents very precise risk estimates under
various shower cubicle construction scenarios (Chowdhury and
Champagne, 2009). Given the potentially very large uncertainties in
the upper bound PFs used to characterise these exposures as risks,
quantification of such relationships between behaviour and cancer
risk, or comparisons of risks associated with specific exposure routes,
are ultimately wholly misleading and have very low utility to
decision-makers.
Overall, population health impact assessment should aim to use ex-
posure data that are as similar as possible with exposure as defined in
the study (toxicological or epidemiological) from which exposure–re-
sponse data are derived. This congruence should be sought in terms of
exposure medium and routes of intake, and in the temporal and spatial
characteristics of those data. In general, the use of animal studies to pre-
dict accurately risk in humans is limited because exposure media and
routes of intake in animal studies seldom represent those experienced
in the humanpopulation. For example, high doses of chloroform admin-
istered to rodents by gavage as a single daily bolus in corn oil have been
associated with tumours, in contrast to administration via drinking
water where carcinogenicity has not been demonstrated even at doses
1000 times higher than typical guideline levels (Butterworth and
Bogdanffy, 1999; Coffin et al., 2000). However, assessment of exposure
in epidemiological studies of DBPs also tends to be limited due to prac-
tical difficulties in adequately characterising the many long-term
exposure-determining habits and environments of study subjects.
3.5. Exposure– and dose–response
The results of population health impact assessments are highly de-
pendent on the data selected to quantify exposure– or dose–response.
In many ways, these data are central to the whole assessment, since
they dictate the hazard, the form of the exposure metric and the type
of health outcome that can be incorporated in the assessment. Where
authors do not pay sufficient notice to (a) the framework within
which such information was intended to be used; or (b) the veracity
and/or validity of this information (i.e. by independently checking the
sources from which these data arise), they risk miscalculating their re-
sults and may misinterpret the actual risk to the target population.
The majority of studies used toxicological dose–response data
(usually upper bound PFs for cancer and RfDs for systemic effects) to
estimate risk according to regulatory risk assessment methods. Three
studies used epidemiological data in estimating exposure–response
functions (Attias et al., 1995; Malcolm et al., 1999; USEPA, 2005). In
the Attias et al. (1995) study, epidemiological risk estimates were ob-
tained from a meta-analysis for THM exposure and bladder cancer
(Morris et al., 1992) where risk estimates were presented for binary
exposure data. In the USEPA (2005) study, OR for binary exposure was
derived from a meta-analysis (Villanueva et al., 2003) for bladder
cancer. For the purposes of sensitivity analysis, risk estimates for binary
exposure data derived from five epidemiological studies and an OR/
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were also used. A similar approach was employed for colon and rectal
cancer, and for foetal loss. Of the studies using toxicological data,
upper bound PFs were most commonly used as they were available
from large regulatory risk assessment databases, such as the USEPA
IRIS. These upper bound PFs result from application of linearised multi-
stage (LMS) model to animal data so as to extrapolate to effects in
humans. Application of LMS in this way generates estimates of non-
zero cancer potency even when that parameter is zero (Crump, 1984):
as such, actual risk may be anywhere below the quoted upper bound
PF and zero (Felter and Dourson, 1998). The USEPA has specifically
employed this method in the regulatory context to set guidelines at
which the excess risk of cancer is essentially too small to estimate, so
that public health is protected. We can say that these upper bound PFs
are characterised by “several hidden political components that should
not be there, if we wish to claim that risk assessment is a scientific
exercise” (Tuomisto, 2005). Those well-acquainted with regulatory
risk assessment have never claimed that risks estimated using PFs are
accurate, even when differences between animals and humans are
disregarded (Hrudey, 2009; Rodricks, 2007). The implications of these
political or risk-management decisions, while made explicit in the orig-
inal literature accompanying the risk assessment (see, for example,
Smith, 1996), appear to have been forgotten in many of the cancer
risk assessments reviewed here, as it is clear that the use of upper
bound PFs will greatly overestimate true cancer risk when applied in
population health impact assessment. Some studies used maximum
likelihood estimates of cancer potency based on modelling of animal
data rather than upper bound estimates so as to reduce the potential
for overestimating the risk (Havelaar et al., 2000), and employed prob-
abilistic definitions of cancer potency (Fehr et al., 2003; Havelaar et al.,
2000) which were propagated into final risk estimates.
Several studies applied PFs developed for exposure through one
pathway of exposure to another (Table 2). For example, PFingestion for a
given THM was applied to the inhalation pathway where PFinhalation
was not available, or for dermal absorption factors. The extrapolation
of exposure-route-specific factors from one route to another has been
described as “at best difficult and at worst invalid” (Bull et al., 1995).
In another study (Black et al., 1996), we found that carcinogenic risks
were overestimated for BDCM, as a PFingestion was not available and
the PF for DBCM was used instead. Since risks are ultimately summed
across pathways and DBPs in this approach to risk assessment, use of
inappropriate PFswhere specific data are not available necessarily over-
estimates risk.
All evidence used in an assessment should be valid at the time
the assessment is carried out. The contents of online databases such
as USEPA IRIS are continually subject to update as new evidence is
reviewed. Understanding the validity of data and recognising which
data should be used in an assessment are key tasks for the risk assessor.
In some of the studies reviewed, outdated PFs were used without
justification or explanation (Table 2), a fact that effectively invalidates
these results. For example, although TCM was previously considered a
genotoxic non-threshold carcinogen, its status has changed consider-
ably in the past two decades as scientific understanding changed, to
the extent that employing a PF for TCM after 2001 was not supported
by scientific evidence. In 1994, in the absence of better information on
the mechanism of its carcinogenicity, the USEPA applied default as-
sumptions of low-dose linearity to TCM, and proposed setting a maxi-
mum contaminant level goal (MCLG) of zero. PFs were thus developed
for TCM which incorporated this presumptive default, in support of
the USEPA's belief that there was no safe level of exposure for chloro-
form (Pontius, 2003). In 1998, a review of new animal data was carried
out which suggested that the available evidence pointed now towards
TCM being a threshold carcinogen. Although the MLCG for TCM was
not initially revised, an ensuing legal petition resulted in USEPA
rescinding its zero MCLG and recommending the use of the RfD in lieu
of PFingestion. Cancer effects related to TCM were then thought to becaused by a nongenotoxic cytotoxic mode of action (Butterworth and
Bogdanffy, 1999) where hepatotoxicity was a prerequisite for car-
cinogenesis to occur (King, 2010; USEPA, 2002b). The USEPA IRIS as-
sessment of the cancer risk of TCM formally noted as early as 2001
that the PF had been rescinded because the RfD—based on assessment
of liver toxicity—was protective for cancer. All of those studies using a
PF for TCM cancer risk after 2001 were carelessly erroneous. The fact
that this was done by so many studies would suggest that the reason
why a PF should not be used for TCM in cancer risk assessment is widely
misunderstood. Risk assessments using linear assumptions about dose–
response of this chemical would grossly overestimate actual risk in
human populations (Butterworth, 2005). Although several studies
used the RfD of 0.01 in place of the PFingestion for TCM by the mid-
2000s, many authors used the rescinded PFs several years later, even
in studies published up to the present day (Fig. 1). Importantly, we
noted that this issue of using outdated PFs is not limited to chloroform,
but also applies to other THMs. For example, at the time of writing, PF
values for BDCMwere still available on the IRIS database that will prob-
ably be revised in the light of recent toxicological evidence (NTP, 2005),
as was done by Health Canada in 2009. As such, we would recommend
that authors making any use of data available from sources such as the
USEPA IRIS database should check that the online information is truly
representative not only of the Agency's actual position, but also of the
best current scientific evidence. Publishing studies that neglect to use
correct, up-to-date TCM data as issued by the USEPA ultimately under-
mines the validity of the risk assessment paradigm andmay lead to un-
necessary public alarm.
The studies that used epidemiological data generallymade use of the
best human-based information available at the time of their publication.
Large, well-conducted epidemiological studies, and meta-analyses and
pooled analyses of such data, are an alternative source of data from
which exposure–response functions (ERF) can be derived, particularly
where there ismechanistic information to support causal interpretation
of the reported associations. In the case of epidemiological studies of
DBPs and bladder cancer, the importance of recognising the lack of a
causal mechanism cannot be overstated. Whereas ERF based on toxico-
logical data can be used to estimate risk of (non-specific) cancer, using
data from epidemiological studies allows the estimation of attributable
risk of specific health outcomes in the target population, so long as the
results are presented alongside a clear description of howwell scientific
evidence supports causality. Where several studies—or several pooled
or meta-analyses—exist, sensitivity analysis should be carried out to
quantify the potential impacts of their use on assessment results.
Interpretation of the results of epidemiological studies on DBPs and
cancer—and their use in risk assessments—requires an understanding
and acceptance of the various uncertainties that influence them. Mea-
surement error in exposure assessment is a major concern, particularly
since retrospective estimation of long-term exposure is difficult in the
absence of reliable monitoring data. Since almost all studies have used
a case–control design in order to be powerful enough to detect modest
effects, there is a potential for recall bias. Several of these studies may
also be subject to bias due to the use of hospital-based controls, where
selection of diseases may not be accurate. In addition, the inaccuracies
present in exposure estimates in these studies are indeed limited by
non-systematic biases that may lead to reduction in precision of risk es-
timates, but the lack of specificity in the exposuremetrics used also con-
fers some advantage when ERFs derived from those studies are applied
in population health impact assessment. Since the putative agents
among the N600 DBPs inwater have not been identified, existing epide-
miological studies have tended to employ relatively simple proxies of
exposure, which may be prone to misclassification of true exposure.
This is evidently a weakness of existing epidemiological studies, but
concentrations of THMs in the drinking water have nonetheless served
asmarkers for unknown putative agents, and consistency in the risk es-
timates for bladder cancermay demonstrate that use of such a surrogate
is in some way indicative of true exposure, and foregoes the need fully
Table 2
Summary of dose/exposure–response functions employed.
Name of study PFs/SFs/RfDs (pathway, value, citation)
Lahey and Connor (1983) TCM
• PFingestion used for oral intake
• Value not presented
• Source of data not presented
Jo et al. (1990) TCM
• PFingestion used for oral intake, inhalation and dermal contact
• TCM= 0.26 (mg/kg-day)−1
• Published PF (upper 95% CI) derived from linearised model applied to single ingestion animal study
Attias et al. (1995) THM4
• Unit risk used for oral intake
• TCM= 0.00000027; BDCM= 0.0000046; DBCM = 0.00000304; TBM= 0.000000304 (units of risk per 1 μg/L)
• Unit risks (upper 95% CI) estimated from toxicological data using multistage and linearised multistage models
Black et al. (1996) THM4
• PFingestion used for oral intake
• TCM= 0.0061; BDCM= 0.062; DBCM = 0.062; TBM= 0.0079 (units of cases/person/lifetime/(mg/kg body weight/dday))
• Published PF (upper 95%): TCM, BDCM and TBM from USEPA (1994); DBCM assumed equivalent to BDCM
HAAs (DCAA and TCAA)
• PFingestion used for ingestion pathway
• DCAA = 0.11; TCAA = 0.083 (units of cases/person/lifetime/(mg/kg body weight/dday))
• PFs from Bull and Kopfler (1991)
Chung et al. (1997) THM4
• Single pathway (presumably ingestion) PF used for oral intake, inhalation and dermal contact
• TCM= 0.00000096; BDCM= 0.00000415; DBCM = 0.0000028; TBM= 0.000000415 (units of (μg/L)−1)
• Unit risks (95% upper bound) obtained using TOX-RISK package (multistage model fitted to animal data)
Malcolm et al. (1999) Epidemiological data used
Havelaar et al. (2000) Bromate
• Ingestion dose–response data applied to oral intake
• Point estimate for dose–response parameter for bromate = 0.0030 kg2/3/mg (units of renal cell cancer induction in rats per mg KBrO3/(kg
body weight2/3))
• Dose–response fitted by two-stage model based on three published studies
Hsu et al. (2001) THM4
• PFingestion used for oral intake
• TCM= 0.0061; BDCM= 0.062; DBCM = 0.0084; TBM = 0.0079 (units of risk per mg/kg/day)
• PFs (95% upper bound) for all THM4 cited as USEPA (1999)
Sadiq et al. (2002) TCM
• PFingestion used for oral intake
• 0.0061 (units of mg/kg/day)
• PF (95% upper bound) from IRIS database, cited as "USEPA (2001)"
Williams et al. (2002) TCM
• PFingestion used for oral pathway and dermal contact; PFinhalation used for inhalation
• PFingestion = 0.0031; PFinhalation = 0.0019 (units of mg kg−1 day−1)
• PFs from California EPA, cited as "OEHHA (2010)"
Fehr et al. (2003) TCM and BDCM
• PFingestion used for oral intake
• PF values not presented
• PF was specified as a) a 95% upper bound point estimate and b) a PDF
• PF fromWHO guidelines cited as "WHO (1993) and WHO (1998)"
Sofuoglu et al. (2003) TCM
• PF (values not presented in paper) from IRIS database, cited as "USEPA (2001)"
Lee et al. (2004) THM4
• PFingestion used for oral intake and dermal absorption. PFinhalation used for inhalation of TCM; PFingestion used for inhalation of BDCM, DBCM
and TBM.
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg/day)−1)
• PFinhalation: TCM= 0.081 (units of (mg/kg/day)−1)
• RfDs used for oral and dermal routes for each THM
• RfD: TCM= 0.01; BCDM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg/kg/day)
• PF s from IRIS database, cited as both "USEPA (1999)" and "USEPA (2002)"; RfDs from USEPA, cited as "USEPA (2002)"
Tokmak et al. (2004) THM4
• Methodology of Lee et al. (2004) is cited as the source of the cancer risk assessment methodology used, but no values for PFs or RfDs are
presented, nor which PFs were used for specific pathways etc.
• Authors confirmed that the same PFs and RfDs were used as in Lee et al. (2004)
USEPA (2005) Epidemiological data used
Kavcar et al. (2006) THM4
• PFingestion used for oral pathway
• TCM= 0.01 (mg/kg/day)−1 (RfD used instead of withdrawn PFingestion); values of PFingestion and RfD for BDCM, DBCM and TBM not presented
• All PFs and RfD from IRIS database, cited as "IRIS (2005)"
Nazir and Khan (2006) TCM
• RfD used for oral pathway (recognised as having replaced PFingestion); however, PFingestion used for dermal contact and inhalation
• RfD = 0.01 mg/kg-day; PFingestion = 0.0061 (mg/kg-day)−1 for dermal and inhalation pathways
• IRIS database, cited as both "US Environmental Protection Agency (1999)" and "US Environmental Protection Agency (2001)"
Uyak (2006) THM4
• PFingestion used for oral pathway and dermal contact; PFinhalation used for inhalation pathway (TCM only)
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg/day)-1)
• PFinhalation: TCM= 0.081 (units of (mg/kg/day)−1)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg/kg/day)
• PFs and RfDs are identical to those in Lee et al. (2004); source cited as "USEPA (1999)"
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Table 2 (continued)
Name of study PFs/SFs/RfDs (pathway, value, citation)
Aslan and Turkman (2007) THM4
• PFingestion used for oral intake and dermal absorption. PFinhalation used for inhalation of TCM; PFingestion used for inhalation of BDCM, DBCM and TBM.
• PFingestion: TCM= 0.0061; BDCM= 0.062; DBCM= 0.084; TBM= 0.0079 (units of (mg/kg/day)−1)
• PFinhalation: TCM= 0.081 (units of (mg/kg/day)−1)
• RfDs used for oral and dermal routes for each THM
• RfD: TCM= 0.01; BCDM= 0.02; DBCM= 0.02; TBM= 0.02 (units of mg/kg/day)
• PFs and RfDs from IRIS database, cited as "USEPA (2002)"
Navarro et al. (2007) THM4
• PFingestion used for oral pathway for brominated THMs only; TCM excluded from cancer risk calculation
• PFingestion for BDCM, DBCM and TBM not presented
• RfD: TCM= 0.01 mg/kg-day
• IRIS database cited as "IRIS (2005)"
Semerjian and Dennis (2007) THM4
• PFingestion used for oral pathway (including TCM) and dermal contact; PFinhalation used for inhalation pathway
• PFingestion: no values presented; PFinhalation: no values presented
• RfD: no values presented
• Authors subsequently provided values of PFingestion: TCM= 0.0061; BDCM= 0.062; DBCM= 0.084; TBM= 0.0079; PFinhalation: TCM= 0.081
• PFs and RfDs from IRIS database, cited as "USEPA (2006)"
Wang et al. (2007a) THM4
• PFingestion used for oral pathway (for THM4) and for inhalation (for BDCM and DBCM); PFinhalation used for TCM and TBM; PFdermal used for dermal
contact
• PFingestion: TCM= 0.0061; BDCM= 0.062; DBCM= 0.084; TBM= 0.079 (units of (mg/kg-day)−1)
• PFdermal: TCM= 0.0305; BDCM= 0.0633; DBCM 0.14; TBM= 0.0132 (units of (mg/kg-day)−1)
• PFinhalation: 0.0805; BDCM= 0.062; DBCM= 0.084; TBM= 0.00385 (units of (mg/kg-day)−1)
• PFingestion (THM4) and PFinhalation (TCM and TBM) from IRIS cited as "IRIS (2005)"; PFdermal from RAIS cited as "RAIS (2005"
Wang et al. (2007b) THM4
• PFingestion used for oral pathway and dermal contact; PFinhalation used for inhalation pathway
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg/day)−1)
• PFinhalation: TCM= 0.000023; 0.0000024; 0.0000018; 0.00000023 (units of (mg/kg/day)−1)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (mg/kg/day)
• All PFs and RfDs from IRIS database cited as "USEPA (2005)"
Baytak et al. (2008) THM4
• PFingestion used for oral pathway (BDCM, DBCM, TBM); RfD used for TCM
• PFingestion: BDCM = 0.0000062; DBCM= 0.084; TBM= 0.079 (units of (mg/kg/day)−1)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (mg/kg/day)
• PFs and RfDs from IRIS database cited as "IRIS (2007)". PFingestion for BDCM is 1000 times too small. PFingestion for TBM is one order of magnitude too
high (perhaps this error is copied fromWang et al. (2007a)).
Viana et al. (2009) THM4
• Type of PF used for oral, dermal and inhalation pathways not stated
• No values are presented; authors subsequently confirmed that PFingestion was used for oral and dermal route (BDCM, DBCM); PFinhalation
used for inhalation (TCM); ingestion of TCM was not considered
• PFingestion and RfDs derived from IRIS, cited as both "USEPA (1990) and USEPA (2006)". PFinhalation for TCM from Williams et al. (2002)
Chowdhury and Champagne
(2009)
THM4
• PFingestion apparently used for inhalation and dermal contact (not made explicit)
• PFingestion: TCM = 0.01 (RfD); BDCM= 0.062; DBCM = 0.0084; TBM= 0.0079 (units of (mg/kg/day)−1)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg/kg/day)
• PFs and RfDs from IRIS database cited as "IRIS (2006)"
Buteau and Valcke (2010) TCM
• Pathway-specific toxicological reference values (TRV) for ingestion and inhalation derived from minimal risk levels (MRL) for non-cancer
effects; TRVingestion also used for dermal contact
• TRVingestion = 0.13 (units of mg/kg/day)
• TRVinhalation = 0.056 (units of mg/kg/day)
• MRLs from ATSDR cited as "ATSDR (1997)"
Chowdhury and Hall (2010)
Retracted
THM4
• PFingestion used for oral pathway (presumably also used for dermal and inhalation routes)
• PFingestion: TCM = 0.01 (RfD); BCDM= 0.062; DBCM = 0.0084; TBM= 0.0079 (units of (mg/kg/day)−1)
• IRIS database cited as "IRIS (2009)"
LaKind et al. (2010) THM4
• Biomonitoring equivalent (BE) values for both cancer and non-cancer outcomes (note that these are only as robust as the underlying
health-based exposure guidelines i.e. PFs and RfDs)
• Cancer
○ BE: TCM = NA (lack of PF); BDCM = 0.15; DBCM = 0.16; TBM= 7.4 (for 10−6 risk level, units of pg/mL blood)
• Non-cancer
○ BERfD (biomarker concentration consistent with the RfD): TCM = 230; BDCM= 20; DBCM = 80; TBM= 130 (units of pg/mL blood)
○ BEPOD (biomarker concentration consistent with the human-equivalent point of departure): TCM= 750; BDCM= 190; DBCM = 270;
TBM = 420 (units of pg/mL blood)
• BEs derived from previously published study
Basu et al. (2011) THM4
• PFingestion used for oral pathway (THM4) and inhalation (BDCM and DBCM); PFinhalation used for inhalation (TCM and TBM); PFdermal used
for dermal contact
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg-day)−1)
• PFdermal: TCM= 0.0305; BDCM= 0.0633; DBCM = 0.14; TBM= 0.0132 (units of (mg/kg-day)−1)
• PFinhalation: TCM= 0.0805; TBM= 0.00385 (units of (mg/kg-day)−1)
• RfDingestion: TCM = 0.01; BDCM= 0.02; DBCM = 0.02; TBM = 0.02 (units of mg/kg/day)
• RfDdermal: TCM = 0.002; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg/kg/day)
• PFingestion, PFinhalation and RfDs from IRIS database, cited as "IRIS (2005)"; PFdermal from RAIS cited as "RAIS (2005)"
(continued on next page)
73J. Grellier et al. / Environment International 78 (2015) 61–81
Table 2 (continued)
Name of study PFs/SFs/RfDs (pathway, value, citation)
Chowdhury et al. (2011)
In italics: updates according to
Chowdhury (2012) response to
commentary Bull et al. (2012)
THM4
• PFingestion used for oral pathway and dermal contact (THM4), and for inhalation (BDCM and DBCM); PFinhalation used for inhalation (TCM and TBM)
• PFingestion: TCM= 0.0061; BDCM= 0.062; DBCM= 0.0084; TBM= 0.0079 (units of (mg/kg/day)−1)
• PFinhalation: TCM= 0.081; TBM= 0.0039 (units of (mg/kg/day)−1)
• PFs from IRIS database cited as "IRIS (2009)", except for TCMwhere already rescinded IRIS data were used
• PFingestion used for oral pathway and dermal contact (BDCM, DBCM and TBM), and for inhalation (BDCM and DBCM); PFinhalation used for inhalation (TBM)
• PFingestion: BDCM= 0.062; DBCM= 0.0084; TBM= 0.0079 (units of (mg/kg/day)
−1)
• PFinhalation: TBM= 0.0039 (units of (mg/kg/day)
−1)
• PFs from IRIS database cited as "IRIS (2009)"
Legay et al. (2011) THM4
• PFingestion used for oral pathway and dermal contact (THM4), and for inhalation (BDCM and DBCM); PFinhalation used for inhalation (TCM
and TBM)
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.079 (units of (mg/kg/day)-1)
• PFinhalation: TCM= 0.081; TBM = 0.0039 (units of (mg/kg/day)−1)
• PFingestion from IRIS database, cited as "IRIS (2009)"; PFinhalation from RAIS, cited as "RAIS (2009)"
• Note: for TCM 2 “scenarios” were used: 1. rescinded PF used; 2. RfD = 0.01 mg/kg/day was used
DCAA
• PFingestion used for oral pathway
• PFingestion = 0.05 (units of (mg/kg-day)−1)
• PF from IRIS database, cited as "IRIS (2009)"
Liu et al. (2011) THM4
• PFingestion used for oral, inhalation and dermal contact pathways
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/(kg day))−1)
• PFs from USEPA, cited as "USEPA (1999) and USEPA (2007)"
Pardakhti et al. (2011) THM4
• PFingestion used for oral pathway and dermal contact; PFinhalation used for inhalation pathway
• PFingestion: TCM = 0.031; BDCM= 0.062; DBCM = 0.084; TBM= 0.0079 (units of (mg/kg day)−1)
• PFinhalation: TCM= 0.0000805; BDCM= 0.13; DBCM = 0.095; TBM = 0.00385 (units of (mg/(kg day)−1))
• PFs from IRIS database, cited as "IRIS (2009)", and from California EPA (no citation presented)
Yamamoto (2011) THM4
• PFingestion used for oral pathway
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg)/day)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg/kg-day)
• PFs and RfD from uncited source
Venkataraman and Uddameri
(2012)
THM4
• PFingestion used for inhalation; details on other pathways not provided
• PFingestion: TCM = 0.01 (RfD); BDCM= 0.062; DBCM = 0.0084; TBM= 0.0079 (units of (mg/kg day)−1)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg/kg-day)
• PFs and RfDs from Chowdhury and Champagne (2009)
Amjad et al. (2013) THM4
• PFingestion used for oral pathway and dermal contact; PFinhalation used for inhalation pathway
• PFingestion: TCM = 0.031; BDCM= 0.062; DBCM = 0.084; TBM= 0.0079 (units of mg kg−1 day−1)
• PFingestion: TCM = 0.0000805; BDCM= 0.13; DBCM = 0.095; TBM = 0.00385 (units of mg kg−1 day−1)
• RfD: TCM= 0.01; BDCM= 0.02; DBCM = 0.02; TBM= 0.02 (units of mg kg−1 day−1)
• PFs from Pardakhti et al. (2011): IRIS database, cited as "IRIS (2009)", and California EPA (no citation presented); RfDs from Lee et al.
(2004)
Gan et al. (2013) THM4
• PFingestion used for oral pathway and dermal contact (THM4) and inhalation (BDCM and DBCM); PFinhalation used for inhalation pathway
(TCM and TBM)
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg/day)−1)
• PFdermal: TCM= 0.035; BDCM= 0.0633; DBCM = 0.14; TBM = 0.0132 (units of (mg/kg/day)−1)
• PFinhalation: TCM= 0.081; TBM = 0.00385 (units of (mg/kg/day)−1)
• PFingestion and PFinhalation from IRIS database, cited as IRIS (2005); PFdermal from RAIS, cited as RAIS (2005). The authors claim to have
accessed this information in 2012, in spite of the fact that some quoted data were rescinded some years previously
HAAs
• PFingestion used for oral pathway
• PFingestion: DCAA = 0.05; TCAA = 0.07 (units of (mg/kg/day)−1)
• PFs from IRIS, cited as "IRIS (2005)"
Lee et al. (2013) THM4
• PFingestion used for oral pathway and dermal contact (THM4) and inhalation (BDCM and DBCM); PFinhalation used for inhalation pathway
(THM4)
• PFingestion: TCM = 0.0061; BDCM= 0.062; DBCM = 0.084; TBM = 0.0079 (units of (mg/kg/day)−1)
• PFinhalation: TCM= 0.081; BDCM= 0.13; DBCM = 0.094; TBM = 0.0039 (units of (mg/kg/day)−1)
• PFingestion (TCM) and PFinhalation (TCM and TBM) from RAIS, cited as "RAIS (2010)"; PFingestion (BDCM, DBCM and TBM) from IRIS, cited as
"USEPA (2011)"; PFinhalation (BDCM and DBCM) from Cal/EPA, cited as "Cal/EPA (2010)" but source unclear
Karim et al. (2013) THM4
• PFingestion used for ingestion and dermal contact
• No values presented for PFs or RfDs
• PFingestion from IRIS, cited as (Lee et al., 2004), and from RAIS, cited as (Wang et al., 2007a); RfDs from USEPA, cited as (Basu et al., 2011; Lee et al.,
2004) and "USEPA (1999)"
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DBPs,whichwould be prohibitively resource-intensive. Importantly, es-
timates of LECR calculated from toxicological data on THMs alone havebeen shown to be some two orders of magnitude lower than those cal-
culated from epidemiological data, where THM concentrations can be
considered a surrogate for an unknown putative agent (Bull, 2012).
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data, these should be applied to the respective strata within the target
population.
In spite of the results of the assessments depending heavily on the
ERF data used, key information was omitted from a number of reports
(Table 2). Specific PFs used in calculating carcinogenic risks were not
reported in 8 studies. In several studies, PFs were quoted that would
not have been in agreementwith cited databases at the time of publica-
tion, or sources of data were cited so vaguely as to make verification of
PFs impossible. In a few studies, no citation was provided whatsoever
for these data. In other cases, the values of PFs reported (and potentially
used) were incorrect. In one case, PFingestion for TBM was reported an
order of magnitude too high (Wang et al., 2007a) — this error appears
to have been reproduced afterwards in another paper (Baytak et al.,
2008). The value reported in one paper for PFingestion for DBCM was an
order of magnitude too low (Chowdhury and Champagne, 2009), an
error that was apparently propagated into two subsequent papers
(Chowdhury and Hall, 2010 (retracted); Chowdhury et al., 2011).
In fact, the Chowdhury & Hall paper was retracted specifically because
the IRIS RfD was erroneously used as though it were a PF (thereby
completely invalidating the results), and the authors did not publish an
erratum when these errors were identified. By graphically representing
the PFingestion from all studies (Fig. 1), it is possible to see that the
same values were used by many studies over a period of 2 decades,
sometimes without paying heed to updated advice regarding the
use of these data. There is considerably more variation over time
among the PFs used for dermal (Fig. 2) and inhalation (Fig. 3) expo-
sure routes, perhaps partly because in studies seeking to include risk
estimation for exposure DBCM and BDCM by inhalation, the authors
either sought alternative data when the USEPA ceased to supportFig. 1. Cancer potency factors for trihalomethanes used fortheir use, or continued using them regardless. The central role that
dose– and exposure–response data play in population health impact
assessment should not be underestimated: these data should be in-
cluded in the reporting of assessments, and unambiguous citations
(including the date of access in the case of online databases) provid-
ed to the sources from which they have been obtained. Full review
of the validity and suitability of these data should be carried out be-
fore using them to characterise risk in a target population.
3.6. Risk characterisation
With some notable exceptions, the overwhelming majority of
studies focused on estimation of cancer risks associated with DBP
exposure, as might be expected given societal concerns about DBPs
as possible human carcinogens. Lifetime excess risk of cancer was
characterised in most studies by multiplying exposures by PFs to
give lifetime cancer risks (after methodology in, for example, Anderson
and USEPA Carcinogen Assessment Group, 1983; USEPA, 1986; Smith,
1996). For non-cancer outcomes, exposure was divided by RfDs to yield
HQ (or their sumacross pathways, hazard index (HI)). Several of the stud-
ies looking at LECR proceeded to calculate the number of lifetime excess
cancer cases in a population by multiplying the estimate of LECR by the
target population of interest.
Three studies used epidemiological data to assess risks in a popula-
tion related to exposure to DBPs. One of these (Attias et al., 1995) esti-
mated the incremental lifetime carcinogenic risk (or unit risk), for a
hypothetical human population subjected to 1 μg/L of TTHM. This was
subsequently used in the sameway as a PF to predict the LECR in a pop-
ulation based on its exposure. The second study estimated the cases of
disease (cancers of the bladder, colon and rectum, and birth defects)ingestion route, by study (presented chronologically).
Fig. 2. Cancer potency factors for trihalomethanes used for dermal route, by study (presented chronologically).
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tributable risk percent (PAR%) using the formula:
PAR% ¼ Pe RR−1ð Þ
1þ Pe RR−1ð Þ
 
 100
where Pe is the proportion of the population exposed, and RR is the
relative risk from an epidemiological study. The result was then applied
to cancer registry and birth defect registry data for one year, and report-
ed as the annual number of cases attributable to DBP contamination of
drinking water. The third study (USEPA, 2005) calculated the PAR asso-
ciated with exposure to DBPs and subsequently number of annual cases
of bladder cancer that would be avoided after the entire population
would have been exposed for a lifetime under new exposure conditions.
In the one study that considered risks of microbial disease (Havelaar
et al., 2000), infection from C. parvumwas estimated using an exponen-
tial dose–response model based on volunteer data. Daily risks were
cumulated over a year to provide an annual risk for the population. In
order to compare between two very different kinds of disease endpoints,
namely renal cell cancer and microbial disease, Havelaar et al. (2000)
transformed estimates of cases of disease into disability-adjusted life
years (DALYs) using clinical data relating to the severity and duration
the diseases in question.
There are a number of clear advantages associated with calculating
attributable risks or cases of disease using human exposure–response
data. Firstly, there is no uncertainty introduced through extrapolating
between species, though there are, of course, limitations to the transfer-
ability of an ERF based on epidemiological data, in particular due to dif-
ferences in other factors contributing to disease (genetics or behaviours,
for example), between the population fromwhich the ERFwas obtainedand the target population of the assessment. Secondly, attributable
cases of specific disease endpoints can be predicted in the target popu-
lation, which is of considerable value to decision-makers. Thirdly, there
is less of a constraint to focus on individual chemicals, for which toxico-
logical datamaybe scarce, or of limited applicability to humans; exposure
proxies used in the epidemiological studies may be considered to reflect
overall exposure to DBPs (albeit with associated loss of precision in the
risk estimates), allowing us to forego assumptions regarding the putative
agent or agents in the DBP mixture.
In a number of the studies calculating LECR, upper bound risk
estimates were further projected onto either hypothetical populations
(Black et al., 1996; Havelaar et al., 2000; Jo et al., 1990) or, most com-
monly, onto the specific population of an area, region or country
experiencing a particular exposure, in order to arrive at an estimate of
the excess cases of cancer that could be expected in such a population
in a year, or over a lifetime. One major weakness to this approach lies
in the multifactorial nature of carcinogenesis, with rates for most can-
cers increasing dramatically with age. Given that the age structure of
those target populations is not taken into account, comparisons of
cases of cancer calculated in this way across different areas are likely
to present a very distorted message to decision-makers. Estimates of
the attributable cases of specific types cancer were presented in those
studies using epidemiological data to quantify exposure–response
(Attias et al., 1995; Malcolm et al., 1999; USEPA, 2005) and as such
this approach ostensibly ought to providemore specific andmeaningful
information to decision makers. However, the estimates of preventable
cancer deaths in New Zealand in 1995 published by Malcolm et al.
(1999) are approximately twice as high as our own estimates for the
New Zealand population in 2012 (not presented), which we calculated
using relative risks from the only meta-analysis available at the time,
Fig. 3. Cancer potency factors for trihalomethanes used for inhalation route, by study (presented chronologically).
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be due to improvements in survival for bladder and colorectal cancers
between 1995 and 2012. However, our own estimates of attributable
burden due to colorectal cancer had wide 95% uncertainty intervals
that included zero and for this reason emphasise that estimates of AFP
and attributable cases be presented with their associated uncertainty
intervals. It is unclear how unit risks were calculated from relative
risks in the Attias et al. (1995) study, and it is not explained in that
study why more easily interpretable estimates of attributable fractions,
for example, were not calculated instead.
Typically the temporal nature of a population health impact assess-
ment is determined by time-related characteristics of the exposure
data. In some cases, demographic or health datamay also be used to de-
fine this temporal scope. In one study, baseline rates of bladder cancer
were averaged over several decades, thereby defining the timescale of
the assessment and implicitly accounting for latency of effects (Attias
et al., 1995). The means by which latency and temporality were explic-
itly considered in the USEPA (2005) study discussed above represent an
example of how to treat these issues. Some assessments that used ERFs
derived from epidemiological data were purely cross-sectional in their
approach, in spite of the fact that they were addressing cancers known
to be characterised by long latency. In studies estimating lifetime cancer
risk, a lifetime of exposure was generally fixed at 70 years; where life-
time cases of cancer were estimated for specific populations, it is hard
to know exactly towhich population such estimates should be assigned.
For example, where a target population is assigned a LECR, this should
be understood to be the number of excess cancer cases estimated for a
population of individuals, each living for 70 years, irrespective of their
current age i.e. for those of 70 years of age and older, this risk is present-
ed for exposure in the past, for those of 69 years of age and under, therisk is presented for exposure yet to occur. Interpreting such a metric
is far from straightforward given the uncertainties in past and future
exposures, and limits the usefulness of such an approach. Also, thismeth-
od takes no account for increases in cancer risk with increasing age. The
effect of not explicitly determining the timeframe of an assessment
may result in estimates of exposure and associated risk being over- or
underestimated unpredictably. In general, when estimating the attribut-
able cases of a disease in a target population, age- and sex-stratified
data should be used, for example:
Attributable cases ¼
X
i; j
Pei j RRi j−1
 
1þ Pei j RRi j−1
 
2
4
3
5  Ii j
100;000
 Ni j
where Peij is the proportion of the target population exposed in i
age groups and for j sexes, RRij is the age- and sex-stratified relative risk,
Iij is the annual incidence of the disease per 100,000 of the target popula-
tion, and Nij is the age- and sex-stratified number of people in the target
population.
Cumulative exposure and latency associated with chronic health
effects (e.g. time between first exposure and development of a cancer)
present themselves as complex issues to the assessor. While cross-
sectional modes are static, in the sense that they use current exposure
and health data to estimate a burden of disease attributable to a cancer,
this is not robust from a temporal standpoint. Such models do not ac-
count for the fact that cancer prevalence rates at the current time reflect
past exposure to contaminants. Historic exposure data are seldom avail-
able for drinking water contaminants due to the relatively recent intro-
duction of monitoring systems. The assessor is then faced with a trade-
off between introducing uncertainties through extrapolating exposure
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future. Historic exposure to drinkingwater contaminants has been esti-
mated in epidemiologic studies by using historical data on treatment
type and source water to build scenarios about levels of DBPs in the
past (e.g. Villanueva et al., 2004); similar approaches could be used to
estimate the population health impacts under baseline conditions. Con-
versely, scenarios can be employed to account for the health impacts of
specific decisions made today, for example regarding treatment tech-
nologies. In either case, it is important to specify precisely the target
populations for which health impacts are being assessed, as well as
the period of exposure and latency periods to which these relate.
Taking account of various aspects of time in population health im-
pact assessments requires consideration of duration, frequency and
temporal variability of exposure, as well as time elapsed between expo-
sure and development of disease (latency). Where data or methods are
insufficient for a thorough consideration of timing, assumptions and
their associated limitations should be described. In most of the studies
reviewed, the temporal nature was generally not stated explicitly, and
time-related limitations were not discussed.
3.7. Scenarios
Some studies explicitly defined scenarios underwhich risk estimates
might be compared in support of decision-making. These scenarios
included different waste disposal policies (Lahey and Connor, 1983),
implementation of carbon removal technologies or alternative water
treatment measures (Black et al., 1996; Sadiq et al., 2002; USEPA,
2005; Wang et al., 2007b; Yamamoto, 2011), water privatisation
policies (Fehr et al., 2003), and chlorination versus no chlorination
(Malcolm et al., 1999). Other studies compared risks under alternative
exposure scenarios, such as showering versus drinking (Jo et al.,
1990), shower design parameters (Chowdhury and Champagne,
2009), shower usage (Nazir and Khan, 2006; Venkataraman and
Uddameri, 2012), and consumption of bottled water versus tap
water (Kavcar et al., 2006). Others compared risks related to differ-
ent kinds of exposure–response data (Attias et al., 1995), or under
different assumptions regarding the carcinogenicity of chloroform
(Legay et al., 2011). Only one study compared the competing risks
associated with disinfection: i.e. risks associated with microbial con-
tamination and with DBPs (Havelaar et al., 2000). Multiple scenarios
relating to changes in regulations and compliance were compared with
three separate sets of baseline conditions in the USEPA (2005) study.
Those studies that did not explicitly define scenarios presented estimates
of risk associated with DBP exposure versus implied counterfactual sce-
narios of zero risk at zero exposure. This approach misses the opportu-
nity of supporting relevant decision-making processes; more
fundamentally, however, the implicit scenario of zero DBPs is neither
plausible nor particularly useful where chemical disinfection is near-
ubiquitous and serves an important purpose in controlling microbial
contamination. Drastic, all-or-nothing scenarios do little to inform pol-
icy if they are not realistic.
Ideally, assessors should be guided by discussion with decision-
makers so that scenarios represent actual or (realistic) potential policy
questions. We were surprised to find only one study that weighed up
the risks (DBPs) and benefits (drinkingwater free of pathogens) associ-
ated with disinfection (Havelaar et al., 2000), given the importance of
such a risk–benefit analysis and the very direct implications of such re-
search to policymakers and drinking water providers. In the most ex-
tensive study reviewed, considerations relating to microbial quality
were accounted for in separate assessments used to develop the regula-
tory scenarios employed in the DBP assessment which did not posemi-
crobial risks to public health (USEPA, 2005). We would argue that
modelling potential effects on health of other hypothetical scenarios re-
lating to DBPs—for example, irrespective of whether they are societally
relevant or politically, technically or economically possible—is ultimate-
ly an inefficient use of scientific resources; identifying themost relevantpolicy questions and building realistic scenarios should form a key part
of the scoping phase of any population health impact assessment.
Narrowing the scope of a population health impact assessment to a sin-
gle contaminant and presenting a risk only against an implicit counter-
factual scenario of zero exposure may lead to inappropriate risk
management decisions. The value of population health impact as-
sessments should be seen in terms of better understanding the
multiple risks in drinking water disinfection and supply so that de-
cisions and policies might be made for the overall improvement of
public health.
3.8. Analysis of uncertainty
In the context of regulatory risk assessment the use of default values
and assumptions is a necessary means of achieving consistency among
evaluations of different hazards. Many of the studies reviewed had
used data based on similar default values and assumptions in spite of
their use outside of the regulatory sphere. Such studies may produce bi-
ased results, and may underestimate uncertainty introduced, for
example, for true variability in characteristics, behaviours and structure
of the target population. These studies would have gained by better
characterising such uncertainties; at the very least many would have
benefitted from documenting possible sources of uncertainty unaccount-
ed for and the limitations that these would impose on their results.
Thorough lists of modelling assumptions, the uncertainties associated
with them, and their potential effects on results were presented in very
few studies.
Studies which included some analysis of uncertainty used a variety
ofmethods, ranging from sensitivity analysis employingdifferent values
of PF, to probabilisticmodelling and comprehensive sensitivity analyses
of stochastic, parametric, model and data uncertainties. The USEPA
(2005) study featured by far the most comprehensive approach to
treat uncertainties—incorporating modelling, simulations, extensive
sensitivity analyses among other approaches—a discussion of which is
outside of the scope of this paper.
The influence of using different data sets, methods or models on re-
sults was investigated in some studies, by presentation of systematic
univariate sensitivity analysis, or, in the majority of studies by using
ad hoc methods of sensitivity analysis. In one study, exposure parame-
ters (some of whichwere defined probabilistically) were systematically
increased by 10% and the effect on the total absorbed dose was calculat-
ed (Buteau and Valcke, 2010). Although this approach yielded useful
information regarding the system being modelled and the parts of that
systemonwhichmore attention should be focusedwith regard to accura-
cy and precision, no attempt was made to assess the sensitivity of the
overall assessment results to potential uncertainties in the ERF,
thereby missing potentially important sources of uncertainty that
might completely alter the findings of the study. Focusing all atten-
tion on the exposure side of the causal chain that is drawn between
hazard, exposure and health risk—and failing to recognise the potential
significance of uncertainties in the ERF in this chain—represents a serious
oversight.
Probabilistic simulation techniques such as Monte Carlo analysis
were used to characterise uncertainty in exposure assessment in a num-
ber of studies (see Table 1). Deterministicmodelling is increasingly con-
sidered as an inappropriate means of assessing uncertain risks (Frey,
1992; Reckhow, 1994; Sander et al., 2006). Employing probabilistic
simulation as ameans of incorporating stochastic and parametric uncer-
tainty into variables within the model, and propagating these uncer-
tainties along the causal chain to the results, allow the assimilation of
various input uncertainties at each step of the modelling process
(Aertgeerts and Angelakis, 2003). Uncertainty in results can then be ap-
portioned to each uncertain input variable through the use of rank
correlation and importance analysis: knowing where the major uncer-
tainties lie in the assessment model provides useful information on
the areas in which additional research or investment might be
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exploited in some studies that characterised exposure with probability
distribution functions, since PFs were still defined deterministically, in
spite of the fact that they may represent a major source of uncertainty
in an LECR assessment. Bootstrappingwas used in exposure assessment
in two studies as ameans of inferring robust non-parametric probability
distribution functions from limited sampling data (Sadiq et al., 2002;
Sofuoglu et al., 2003). One method proposed for assessing effects on
health of DBPs lacking detailed toxicity data is fuzzy synthetic evalua-
tion (Sadiq and Rodriguez, 2004). Fuzzy sets can be parameterised
using weights derived from the carcinogenicity potential ranking system,
and arbitrary weights can then be assigned to these sets when they are
‘defuzzified’. The advantages of this approach are that it enables a synthe-
sis of cancer and non-cancer risks in one framework; where data are
available only in non-commensurate units, vagueness in definitions can
be propagated through a causal framework; and the modular form of
themethodology is fully scalable to anynumber of possible contaminants,
and health effects etc. The chief limitation of such an approach is that re-
sults are highly sensitive to the selection of weights and aggregation op-
erators, which can usually be derived only by using expert opinion.
Population health impact assessment cannot always be a precise sci-
ence. In producing a scientific answer to a real-world policy problem re-
lating to DBPs, it is usual to make several assumptions, use data of
different levels of precision, and employ methods subject to numerous
caveats and limitations. These should be recorded, alternatives ex-
plored, and results presented in the context of their limitations. In gen-
eral, it is worthwhile considering the degree of uncertainty of each
component of the risk modelling exercise, and assessing whether
these are proportional to one another. There is little to be gained from
producing very precise exposure estimates if the resolution of that
data is later clouded by themuch poorer precision of the risk character-
isation data or methods, for example.3.9. Interpretation and presentation of assessment results — risk
communication
Given the current lack of conclusive evidence of causation of health
outcomes among humans exposed to DBPs, any assessment of health
risks should be presented alongside a clear acknowledgement of the de-
gree to which results depend on the assumption of causation; such in-
formationwas largely absent from the vastmajority of papers reviewed.
Several studies purported to estimate the cases of cancer attributable
to exposure to DBPs, when in fact these estimates are characterised by
large uncertainties, and determined partly by embedded value judge-
ments that constitute a part of the regulatory risk framework-based
methods and data used. In some cases, policy recommendations made
by these studies are disproportionate with the results when viewed in
the context the methods used. For example, some studies recommended
the substitution of current disinfection treatments (chlorination) with al-
ternatives (e.g. ozonation, chloramination) even when the number of ex-
cess cancer cases was negligible over the 70-year lifetime for which they
were estimated (Aslan and Turkman, 2007; Chowdhury and Champagne,
2009). In such studies, thepotential societal or economic cost implications
of such changes were seldom considered, in particular in terms of the po-
tential risks associated with alternative treatments, including other DBPs,
for example.
Maps of cancer risk were presented in three studies (Karim et al.,
2013; Legay et al., 2011; Venkataraman and Uddameri, 2012) and several
of thesewere based on interpolation, usingmodels thatwere veryweakly
supported by data. From a risk communication perspective, presenting
high resolution maps of cancer risk runs the danger of masking the
much lower resolution and precision of exposure data and ERFs used;
the public may imagine that interpolated levels of exposure are reliable
and representative of their true state of risk. Apparent spatial inequalities
may be little more than artefacts of the overall modelling process.It is crucial that adequate care is taken in the presentation of results
of potentially sensitive assessments. One attributable cancer risk assess-
ment reported that the “total cancer risk analysis indicates that Izmir
residents could get cancer from the daily intake of water” (Aslan and
Turkman, 2007). Such pronouncements are not helpful for policy-
makers and could grossly mislead the public and decision-makers. In
the context of developing countries where the threat of waterborne dis-
ease is particularly serious, presentingwhat appears to be a scientifically
irrefutable claim of disinfection as the cause of cancer may result in un-
founded public alarm and bad public health decisions. Ideally, results
should be presented in the context of themany uncertainties that char-
acterise them, with recognition of the assumptions that were made to
facilitate the assessment, andwith due consideration of other risks asso-
ciated with any recommendations made.
4. Conclusions
We reviewed 40 published studies presenting estimates of the
public health impacts associated with DBPs in drinking water. With a
few notable exceptions, all assessments had weaknesses which we be-
lieve seriously reduce the reliability and utility of their results. Firstly,
the majority of these studies used upper bound cancer potency factors
derived from animal studies to estimate generic lifetime cancer risk or
cancer cases attributable to exposure to THMs, the most commonly
monitored DBPs, in a particular region or city. Regulatory risk assess-
ment methods and exposure–response data designed for these pur-
poses are intended to overestimate risks (often by an unknown
margin) so as to be protective of public health. As such, we consider
them inappropriate for accurately predicting realistic levels of risk in
target populations. In addition, the lack of specificity of the health
outcomes predicted by such methods greatly limits their usefulness
in decision-making. We would consider the use of epidemiological
data derived from large, well-conducted studies to provide much
more accurate, robust and scientifically rigorous estimates of risk in target
populations. Many studies were limited by only themost superficial con-
siderations of the true complexity of the occurrence, physicochemical
properties and potential relative toxicity of the vast array of chemicals
comprising theDBPmixture present in typical chlorinated tapwater sam-
ples. Additionally, the benefits attributable to disinfection (in terms of re-
duction of microbial disease) were not considered in the vast majority of
studies. Poor characterisation of exposure in the target population, little
consideration of the temporally heterogeneous character of that ex-
posure, and a lack of specificity in terms of health outcomes and
population characteristics were identified in many of the studies
reviewed. Focusing on specific DBPs in the absence of a mechanistic
explanation or a true putative agent in the DBP mixture may result
in inappropriate or expensive decisions being made in favour of al-
ternative disinfection treatments that may present other health
risks, a point convincingly made by Bull (2012).
In this paper we have argued that the use of inappropriate data that
inflate risks should be avoided. Only through considered and transpar-
ent use of appropriate data,modelling and assumptions, can any assess-
ment of health impacts relating to DBPs be expected to provide useful
information to support policy in this area. To our mind, the population
health impact assessment should be, above all, a transparent and strin-
gent scientific exercise carried out to provide the best possible answer
to a relevant policy question or risk management decision. This might
consider any aspect of the systemof relevance to the policy, such as pos-
sible health effects of alternative water sources, treatment methods or
behaviours relating to drinking water, and should consider these in
terms of other resulting changes in competing risks such as microbial
contamination. The perception that population health impact assess-
ment can be carried out as a simple add-on to an exposure assessment
study greatly limits the usefulness of the assessment results. Currently,
we consider that, with very few exceptions, existing studies add very lit-
tle to our understanding of public health implications of DBP exposure,
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which might lead to poor decisions being made by policy-makers and
drinking water providers. Future studies should focus on answering
real-world policy questions regarding the quality of drinking water,
including consideration of both microbial and chemical parameters.
They should use up-to-date, appropriate and robust data and methods
to answer these questions, and be transparent in explaining the various
uncertainties that affect their results, including their quantification
where appropriate. While we recognise that the tremendous effort
and resources employed by USEPA (2005) in conducting an economic
assessment are not typically available to small groups of researchers
working in this field, many of the principles underlying that approach
can and should be adopted in all health impact assessments relating
to DBPs.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.envint.2015.02.003.
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